The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI b...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Asia Pac J Clin Oncol
Egile Nagusiak: Sakata, Yoshihiko, Kawamura, Kodai, Shingu, Naoki, Hiroshige, Shigeo, Yasuda, Yuko, Eguchi, Yoshitomo, Anan, Keisuke, Hisanaga, Junpei, Nitawaki, Tatsuya, Nakano, Aiko, Ichikado, Kazuya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379949/
https://ncbi.nlm.nih.gov/pubmed/30506897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13103
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak